Articles from MeMed

MeMed, a global leader in host-response diagnostics, today announced a major milestone: more than 100,000 patients have now been tested with MeMed BV®, the company’s flagship diagnostic that accurately distinguishes between bacterial and viral infections in just 15 minutes, based on the body’s immune response. This milestone highlights MeMed’s commitment to advancing precision medicine, empowering responsible antibiotic use by care providers, and transforming infection management across diverse care settings.

MeMed, a leader in host-response diagnostics, today announced the publication of three new peer-reviewed studies, reinforcing the real-world clinical and economic impact of MeMed BV, its flagship diagnostic for differentiating between bacterial and viral infections. Conducted across multiple centers in the U.S., Europe, and the U.K., and involving thousands of patients, these independent studies highlight distinct aspects of MeMed BV’s impact, including better antibiotic stewardship, superior performance over the standard of care, and reduced healthcare costs.

MeMed, a leader in host-response diagnostics, today announced the addition of three distinguished experts to its advisory board to accelerate its mission of addressing the global challenges of sepsis and antimicrobial resistance (AMR) through innovative diagnostic solutions. These new members bring decades of experience in medicine, industry, and healthcare policy, strengthening MeMed’s work in host-response technologies, which combine machine learning with rapid measurements of the immune response to transform infectious disease care.

MeMed, a leader in the emerging field of advanced host response technologies, today announced that the FDA has granted Breakthrough Device Designation (BDD) to its innovative MeMed Severity™ test. This designation underscores the transformative potential of MeMed Severity to advance the management of patients with suspected acute infections and suspected sepsis by empowering clinicians with timely, data-driven, clinical insights.

Contract awarded under the BARDA DRIVe (Division of Research, Innovation, and Ventures) initiative to harness a patient's systemic response to inform on health threats and clinical impact

FDA Clears Pioneering MeMed BV Test Direct From Whole Blood Allowing Faster Time To Result And Broader Patient Access When Distinguishing Bacterial From Viral Infections